has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the development and commercialization of Antibody-Drug Conjugates (ADC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback